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disease-childrenAbstract Hashimoto’s encephalopathy is a neurological disorder of unknown etiology associated
with thyroid autoimmunity. The disease may present as two types, a sudden vasculitic type or a pro-
gressive subacute type associated with cognitive dysfunction, confusion and memory loss.
We report a case of a 6 year old previously healthy Egyptian female , who developed a subacute
onset of declining upper brain function. Serologic studies demonstrated high levels of antithyroid
antibodies. Electroencephalographic and magnetic resonance image ﬁndings were consistent with
Hashimoto’s encephalopathy.
Hashimoto’s encephalopathy is a diagnosis of exclusion. This unusual disorder is often underrecog-
nized because of multiple neurocognitive manifestations; therefore, it is important to be aware of
the clinical manifestations to make a correct diagnosis.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Hashimoto’s encephalopathy (HE) is a rare condition associ-
ated with Hashimoto’s disease. Hashimoto’s thyroiditis (HT)
is a common form of chronic autoimmune thyroid diseases.1
The cause of HE has been proposed to be autoimmune because
of its association with other immunologic disorders (myasthe-
nia gravis, glomerulonephritis, primary biliary cirrhosis, perni-
cious anemia and rheumatoid arthritis), female predominance,inﬂammatory ﬁndings in the cerebrospinal ﬂuid (CSF) and
response to treatment with steroids.2,3 HE consists of two
sub types. The ﬁrst is an insidious, recurrent vasculitic type,
demonstrating stroke-like attacks concomitant with impair-
ment of consciousness, and the second is progressive and the
more commonly seen form of encephalopathy, which presents
itself with confusion, psychosis, somnolence and coma.4,5 The
underlying mechanism in both HE and HT is autoimmunity.
Two possible mechanisms were suggested in the development
of HE. The ﬁrst of these might be the result of edema and
reduction in the vasculature due to autoimmune mediated cen-
tral nervous system vasculitis together with impairment of the
microvascular structure. The other is the formation of antineu-
ral antibodies and cross-reaction due to a common antigen of
both the thyroid gland and the brain.6
Figure 1 U/S on the thyroid gland showed a picture of chronic thyroiditis (hypoechogenic lobes).
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A six year old Egyptian female child fourth in order out of ﬁve
off spring, of positive consanguinity was admitted to the hospi-
tal complaining of hypo activity (her level of functioning prior
to illness had been adequate, subsequently returning to a simi-
lar level after recovery from episodes) and changed sensorium
(changes in level of consciousness, confusion and delirium).
The patient suffered from cognitive impairment, emotional
instability and amnesia according to her mother. There was
also weakness of her left leg with gradual onset and ﬂuctuating
course. She was 106 cm tall (within normal percentile) and
weighed 23.6 kg (within normal percentile), for a body mass
index of 21 kg/m2. Her neurological examination revealed a
focal neurologic deﬁcit with hypotonia and hyperreﬂexia. Her
speech showed lack of ﬂuency and hesitation. Cranial nerves
and sensory examination showed no abnormalities. About
one month before, the patient was hospitalized for altered con-
sciousness, hallucinations for which the patient had a lumbar
puncture (LP) twice during her two weeks stay in hospital.
The patient was given non-speciﬁc supportive treatment, exceptfor L-thyroxin for the hypothyroid state (ﬂFT3, ﬂFT4 and
›TSH). Following this, the patient was discharged with no sat-
isfactory response. There is a positive family history: The girl’s
mother has type 1 diabetes mellitus (T1DM) and normal thy-
roid proﬁle and her aunt has Hashimoto thyroiditis that was
diagnosed based on raised thyroid auto antibodies in serum,
sonography andﬁne needle biopsy. There was a history of
admission to neonatal intensive care for about 9 days and trea-
ted for possible insulin dependent diabetes. The patient’s vacci-
nations were up to date and she was developmentally normal.
The following investigations were done: complete blood count
(CBC) and serum electrolytes the results of which were within
normal limits; liver and kidney function tests were also normal.
Erythrocyte sedimentation rate (ESR) 1st hour was 30 mm/h.
Anti nuclear antibodies (ANA) and anti double stranded
DNA were negative.
Other speciﬁc tests included:
Thyroid proﬁle: Free T3 <0.40 mmol/l (Ref. range: 0.90–
300.0), Free T4 <6.00 mmol/l (Ref. range: 5.50–140.0), and
thyroid stimulating hormone (TSH) was increased to
>60.00 ulU/ml.
Figure 2 The ﬁrst EEG evaluation done at the time of hospital admission showing slowing of background activity on an
electroencephalogram.
Figure 3 The second EEG evaluation done 3 weeks after clinical resolution showing a normal electroencephalogram record.
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56 mg/dl (Ref. 15–45 mg/dl), glucose of 48 mg/dl (Ref. 40–
70 mg/dl). Total leukocytic count (TLC) was normal and
C/S was negative.
Ultrasound (U/S) on thyroid gland: Showed picture of
chronic thyroiditis (hypoechogenic throid lobes), with normal
size of both lobes and the isthmus (Fig. 1).Electroencephalogram (EEG): EEG was done twice, ﬁrst at
the time of hospital admission, showing slowing of back-
ground activity and second 3 weeks after hospital discharge
showing a normal record (Figs. 2 and 3).
Brain computerized tomography (CT): Done at the time
of hospital admission, revealing unremarkable ﬁndings
(Fig. 4).
Figure 4 CT brain showing normal ﬁndings, no abnormal density.
Figure 5 MRI brain showing normal ﬁndings, no abnormal density.
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after clinical resolution of encephalopathy. It was normal; with
no signiﬁcant abnormal signal intensity in T2 weighted images
(Fig. 5).
Autoimmune thyroid disease proﬁles:
Anti-thyroid antibodies: Antithyroglobulin Abs (positive)
and Anti thyroid peroxidase Abs (positive), (also referred to
as antimicrosomal Abs). About 2 weeks from hospital dis-
charge, the patient. was subsequently given steroid therapy,
we applied the approach which advocates a dose of oral pred-
nisone at 60 mg/m2/day for 10 days till now, for a total of14 days then gradually withdrawn. Dramatic recovery was
achieved, regarding good concentration, appropriate answers
and satisfactory interest.
Results of our investigations are illustrated as follows:Discussion
The term HE is now commonly used for the few hundred
patients published so far. Since there is no evidence that
antithyroid antibodies have a role in pathogenesis, this term
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‘‘Steroid Responsive Encephalopathy associated with
Autoimmune Thyroiditis’’.7 However, till the pathogenesis is
under stood, the eponym ‘‘HE’’ seems to be the most appropri-
ate name for the condition because it links the only known
identiﬁer, high serum concentrations of antithyroid antibod-
ies.8 In this case report, we discussed the importance of consid-
ering the diagnosis in the evaluation of acute or sub acute
confusional state. The exact pathology of HE is unknown,
but autoimmune mechanisms have been suggested because of
its higher prevalence in females, ﬂuctuating course, association
with other autoimmune disorders and dramatic improvement
on steroid therapy.9
Differential diagnosis
It is to be noted that any probable causes of encephalopathy
should be ruled out such as infection, electrolyte imbalance,
toxins, metabolic, degenerative causes or neoplasm. Over the
last 40 years, the diagnosis of this condition has been hindered
by lack of universally agreed upon diagnostic features. In
response to this ambiguity, clearly deﬁned criteria have been
delineated and include encephalopathy with neurological signs,
presence of antithyroid antibodies; even in the presence of the
euthyroid state; and response to steroid therapy.10 Laboratory
evaluations are critical in making the diagnosis and will typi-
cally show an elevated serum level of antithyroid peroxide
antibody. CSF is abnormal in approximately 80% of patients,
usually revealing an elevated CSF protein level. EEG abnor-
malities seen in HE vary from epileptiform abnormalities, gen-
eralized slowing to normal ﬁndings.11 Regarding brain
imaging studies; In a review of 82 patients with HE, brain com-
puted tomography or MRI showed abnormalities in 49% such
as cerebral atrophy, focal cortical abnormality, diffuse subcor-
tical abnormality and nonspeciﬁc subcortical focal white mat-
ter abnormality.12
The acute confusional state seen in HE is recognized as not
related to the thyroid status. Correction or near correction of
thyroid function abnormalities is frequently required for the
diagnosis of this condition. This condition must be considered
separate from confusion related to the thyroid disease since the
addition of immunomodulating agents will be required for its
speciﬁc treatment.13 The long-term prognosis is variable,
although a high percentage of patients respond to treatment;
others could have a progressive or a relapsing course. The
symptoms usually improve with glucocorticoid therapy; how-
ever, it is not necessary because of treatment. A systematic
review of 85 cases published of HE found clinical response
in 98% of patients treated with glucocorticoids, 92% of
patients treated with glucocorticoids and levothyroxine and
67% of patients treated with levothyroxine only.14
HE is difﬁcult to diagnose. Too often patients are misdiag-
nosed at the neurological level. It is known that if Hashimoto’s
encephalopathy goes untreated it results in irreversible demen-
tia, coma, nursing home and death.
Just one person misdiagnosed is not acceptable, especially
when there are so many resources available to assist proper
diagnosis and appropriate treatment. The disease is notcurable but treatable and with appropriate treatment, the
long-term prognosis is good.15
Conclusion
Any patient presenting with acute or subacute unexplained
encephalopathy should be considered as having HE, even if
thyroid functions are normal. Thyroid antibody testing should
be performed because it is the most important clue to the diag-
nosis. So, considering its reversible course, it is recommended
that HE should be always kept in mind while evaluating disor-
ders of the central nervous system.
N.B.: Written consent was obtained from the mother of the
patient for publication of the case report and any accompany-
ing images.
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